Chronic treatment with d-chiro-inositol prevents autonomic and somatic neuropathy in STZ-induced diabetic mice
Article first published online: 24 JAN 2011
© 2011 Blackwell Publishing Ltd
Diabetes, Obesity and Metabolism
Volume 13, Issue 3, pages 243–250, March 2011
How to Cite
Farias, V. X., Macêdo, F. H. P., Oquendo, M. B., Tomé, A. R., Báo, S. N., Cintra, D. O. S., Santos, C. F., Albuquerque, A. A. C., Heimark, D. B., Larner, J., Fonteles, M. C., Leal-Cardoso, J. H. and Nascimento, N. R. F. (2011), Chronic treatment with d-chiro-inositol prevents autonomic and somatic neuropathy in STZ-induced diabetic mice. Diabetes, Obesity and Metabolism, 13: 243–250. doi: 10.1111/j.1463-1326.2010.01344.x
- Issue published online: 24 JAN 2011
- Article first published online: 24 JAN 2011
- Accepted manuscript online: 24 NOV 2010 01:12PM EST
- Date submitted 29 August 2010; date of first decision 28 September 2010; date of final acceptance 11 November 2010
- autonomic neuropathy;
- diabetic neuropathy;
- experimental pharmacology;
- microvascular disease;
- somatic neuropathy;
- therapy of diabetic complications
Aim:d-chiro-inositol (DCI) has been shown to prevent and reverse endothelial dysfunction in diabetic rats and rabbits. The present study evaluates the preventive effect of DCI on experimental diabetic neuropathy (DN).
Methods: Streptozotocin-induced (STZ) diabetic mice were treated by oral gavage for 60 days with DCI (20 mg/kg/12 h) or saline (NaCl 0.9%; 0.1 ml/10 g/12 h; Diab) and compared with euglycaemic groups treated with saline (0.1 ml/10 g/12 h; Eugly). We compared the response of the isolated sciatic nerve, corpora cavernosa or vas deferens to electrical stimulation.
Results: The electrically evoked compound action potential of the sciatic nerve was greatly blunted by diabetes. The peak-to-peak amplitude (PPA) was decreased from 3.24 ± 0.7 to 0.9 ± 0.2 mV (p < 0.05), the conduction velocity (CV) of the first component was reduced from 46.78 ± 4.5 to 26.69 ± 3.8 ms (p < 0.05) and chronaxy was increased from 60.43 ± 1.9 to 69.67 ± 1.4 ms (p < 0.05). These parameters were improved in nerves from DCI-treated mice (p < 0.05). PPA in the DCI group was 5.79 ± 0.8 mV (vs. 0.9 ± 0.2 mV—Diab; p < 0.05) and CV was 45.91 ± 3.6 ms (vs. 26.69 ± 3.8 ms—Diab; p < 0.05). Maximal relaxation of the corpus cavernosum evoked by electrical stimulation (2–64 Hz) in the Diab group was 36.4 ± 3.8% compared to 65.4 ± 2.8% in Eugly and 59.3 ± 5.5% in the DCI group (p < 0.05). Maximal contraction obtained in the vas deferens was 38.0 ± 9.2% in Eugly and 11.5 ± 2.6% in Diab (decrease of 69.7%; p < 0.05), compared to 25.2 ± 2.3% in the DCI group (p < 0.05 vs. diabetic). Electron microscopy of the sciatic nerves showed prevention of neuronal damage.
Conclusions: DCI has a neuroprotective action in both autonomic and somatic nerves in STZ-induced DN.